SCHEMBL5135902

SCHEMBL5135902

CCCCN(Cc1ccc(OCC)c(OCC)c1)Cc1c(-c2ccc(OC)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
ATP4A P20648 4/20 0.40
ATP4B P51164 4/20 0.40
BCHE P06276 3/20 0.37
DRD2 P14416 4/20 0.37
DRD3 P35462 4/20 0.37
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
GAA P10253 3/20 0.37
LMNA P02545 2/20 0.37
TSHR P16473 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PDE4B Q07343 1/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136072 0.94 C5AR1 (0.43) C5AR1BCHEKDM4EALDH1A1GAA
SCHEMBL651447 0.94 C5AR1 (0.46) C5AR1ATP4AATP4BBCHEKDM4E
SCHEMBL5136633 0.91 ATP4A (0.45) C5AR1ATP4AATP4BBCHEDRD2
SCHEMBL5072435 0.91 C5AR1 (0.46) C5AR1BCHEKDM4EALDH1A1GAA
SCHEMBL5137661 0.90 C5AR1 (0.43) C5AR1ATP4AATP4BBCHEDRD2
SCHEMBL5135871 0.90 ATP4A (0.44) C5AR1ATP4AATP4BBCHEDRD2
SCHEMBL5137164 0.89 C5AR1 (0.44) C5AR1ATP4AATP4BBCHEDRD2
SCHEMBL5136576 0.89 C5AR1 (0.42) C5AR1ATP4AATP4BBCHEDRD2
SCHEMBL5070096 0.88 ATP4A (0.50) ATP4AATP4BDRD2DRD3
SCHEMBL647764 0.88 C5AR1 (0.47) C5AR1KDM4EALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed